Flow-through Plasma circuit pathogen reduction device for patients with sepsis and/or liver failure

败血症，血液中大量微生物感染，是一种潜在的致命疾病。抗生素是治疗的主要手段，但无法应对压倒性的败血症，随着耐药细菌的发展，抗生素的效果将逐渐降低。脓毒症也是肝功能衰竭患者死亡的关键原因之一。今天，随着抗生素耐药性的不断增加，迫切需要新的方法来对抗任何病因的败血症。用于重症监护病房的病原体减少流动模块（PRT）将是重症监护医学的重大突破。血浆微生物有意义的减少将使传统的抗微生物治疗再次有效，并将使全世界的患者受益。该项目将满足这一需求。它将以伦敦大学学院开发的一个成熟的创新概念为基础，设计、制造、演示和测试（使用体外模型）一个人体尺度的原型。这项工作将为合作伙伴产生新的可保护的知识产权，并使他们能够根据相关临床和商业利益相关者的投入，制定和冒险开发和推出商业级设备的商业计划。

Sepsis, overwhelming microbial infection of the bloodstream, is a potentially fatal condition. Antibiotics are the mainstay of treatment, but cannot cope with overwhelming sepsis, and as resistant bacteria develop, antibiotics will become progressively less effective. Sepsis is also one of the key reasons for patient demise in liver failure. Today, with ever increasing antibiotic resistance, new approaches are urgently required to combat sepsis from any aetiology. A flow-through pathogen reduction module (PRT) for use in intensive care units would be a major breakthrough for intensive care medicine. A meaningful reduction of plasma microbes would enable conventional antimicrobial treatments to be effective once more, and would deliver benefit to patients worldwide. The project will address this need. Building on a well-developed, innovative concept developed by UCL it will design, manufacture, demonstrate and test (using in vitro models) a human scale prototype. The work will generate new protectable IP for the partners, and enable them to develop and derisk business plans for the development and roll-out of a commercial grade device, building on input from relevant clinical and commercial stakeholders.